Osteoarthritis in dogs: do pentosan polysulfate injections improve lameness and joint scores? — POSSIBLE

In dogs with osteoarthritis, do pentosan polysulfate injections vs placebo improve lameness and joint scores?

Shelf #512 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: Pentosan polysulfate injections improved clinical scores versus placebo in two randomised trials in dogs with osteoarthritis, while the one long double-blind trial of the oral form found no clinical benefit. In Read 1996 (double-blind dose-response study, 40 dogs with chronic osteoarthritis), dogs receiving subcutaneous pentosan polysulfate had a favourable response compared with placebo for lameness, body condition, pain on joint manipulation and willingness to exercise, with 3 mg/kg the best dose (1 mg/kg partially effective, 5 mg/kg least effective; that record gives no scores or P values). In Stapledon 2026 (randomised, placebo-controlled, 20 dogs with naturally occurring osteoarthritis), weekly subcutaneous pentosan polysulfate 3 mg/kg for six weeks gave sustained Helsinki Chronic Pain Index reductions versus placebo at 26 weeks after adjustment for baseline pain, with normalisation of gait symmetry and increased total cartilage volume at weeks 8 and 26. Against these, Innes 2000 (double-blind, placebo-controlled, one year) found oral calcium pentosan polysulphate made no difference to functional outcome or radiographic progression in stifle osteoarthritis after cruciate surgery — for the oral form, the treatment made no difference on those outcomes. Design class (a): randomisation and blinding are both established by carded records — Read 1996 and Innes 2000 are each stated to be double-blind in their own wording, carry publication type Randomized Controlled Trial and MeSH Double-Blind Method; Stapledon 2026 states randomisation (publication type Randomized Controlled Trial, Veterinary) but its record does not state blinding and none is claimed for it. The honest limits: the positive injection trials are small (40 and 20 dogs), Read reports no numbers, Stapledon's placebo arm is only 6 dogs and its treated group started with much higher pain scores (Helsinki Chronic Pain Index 15.14 vs 8.83), and the outcomes are clinical scores, gait symmetry and imaging/biomarker measures rather than hard endpoints. Mixed routes and small samples keep the stamp at POSSIBLE. Drafted Nov 10, 2026 (VetMed build, topic #512); all figures from abstracts fetched and verified at drafting.

Read 1996: in a double-blind dose-response study, dogs on pentosan polysulfate injections improved versus placebo on lameness, pain on joint manipulation and willingness to exercise — 3 mg/kg was the best dose

Double-blind clinical dose-response study (record's own wording: 'a double-blind clinical dose-response study'; publication type: Randomized Controlled Trial; MeSH includes Double-Blind Method)

Who: Dogs: 40 dogs diagnosed as having chronic osteoarthritis, after complete physical examination to ensure good general health, in a clinical setting. Dogs received four subcutaneous injections at intervals of one week of 0 (placebo), 1, 3 or 5 mg/kg pentosan polysulphate from code-numbered bottles. At weekly intervals and four weeks after the last injection, weakness, stiffness, pain on joint manipulation, willingness to exercise, body condition and overall response were scored.

Result: There were no differences between groups in baseline data, but dogs receiving pentosan polysulphate had a favourable response compared to dogs receiving placebo for lameness, body condition, pain on joint manipulation and willingness to exercise. The 3 mg/kg dose rate gave the best improvement, the 1 mg/kg dose was partially effective and the 5 mg/kg group was least effective. The record's conclusion was that pentosan polysulphate at 3 mg/kg is indicated for the treatment of clinical osteoarthritis in dogs. The record gives no group scores or P values, so the size of the improvement cannot be stated from this record.

Watch out: The abstract reports direction of effect only — no scores, no P values, and only about 10 dogs per dose group. The dose response is non-monotonic (5 mg/kg least effective), which the record does not explain. Outcomes are clinician-scored signs (lameness, stiffness, pain on manipulation), not objective gait measurement.

Read RA, Cullis-Hill D, Jones MP. Systemic use of pentosan polysulphate in the treatment of osteoarthritis. J Small Anim Pract. 1996;37(3):108-14. PMID: 8683953. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents, Non-Steroidal/administration & dosage* · Dog Diseases/drug therapy* · Dogs · Double-Blind Method · Female · Injections, Subcutaneous/veterinary · Male · Osteoarthritis/complications, drug therapy, veterinary* · Pentosan Sulfuric Polyester/administration & dosage* · Severity of Illness Index · Treatment Outcome

Innes 2000: oral calcium pentosan polysulphate made no difference to functional outcome or radiographic progression over one year in stifle osteoarthritis after cruciate surgery

Double-blind, placebo-controlled clinical trial (record's own wording: 'a double-blind, placebo-controlled clinical trial'; publication type: Randomized Controlled Trial; MeSH includes Double-Blind Method)

Who: Dogs: dogs with osteoarthritis of the stifle joint secondary to cranial cruciate ligament deficiency, treated surgically, in a clinical setting. Dogs were matched for bodyweight and randomly assigned to treatment or placebo groups. Active treatment began six weeks postoperatively and consisted of 10 mg/kg calcium pentosan polysulphate orally, once weekly for four weeks, repeated every 12 weeks, over a period of one year. Outcomes were owner-assessed function, radiographical grading of osteoarthritis, and synovial fluid glycosaminoglycan and keratan sulphate (5D4 epitope) measures.

Result: There were no differences either in functional outcome or in the radiographical progression of osteoarthritis between the two groups. Fifty-four weeks after surgery, the concentration of 5D4 in synovial fluid (expressed as change from baseline values) had decreased significantly in the treatment group compared with the placebo group (P = 0.03) — a biomarker change without a matching clinical or radiographic benefit.

Watch out: This is the ORAL calcium form in a post-surgical cruciate-deficient stifle population — not the subcutaneous sodium form in primary osteoarthritis that the positive trials tested — so its null result bounds the claim by route and population rather than refuting the injection evidence directly. It is the longest and one of the best-blinded trials carded here, and on clinical outcomes it is flatly null; only a synovial biomarker moved.

Innes JF, Barr AR, Sharif M. Efficacy of oral calcium pentosan polysulphate for the treatment of osteoarthritis of the canine stifle joint secondary to cranial cruciate ligament deficiency. Vet Rec. 2000;146(15):433-7. PMID: 10811265. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents, Non-Steroidal/therapeutic use* · Biomarkers/analysis · Dog Diseases/diagnostic imaging, drug therapy*, etiology · Dogs · Double-Blind Method · Ligaments, Articular/pathology, surgery · Osteoarthritis/diagnostic imaging, drug therapy, etiology, veterinary* · Pentosan Sulfuric Polyester/therapeutic use* · Radiography · Stifle · Surveys and Questionnaires · Synovial Fluid/chemistry

Stapledon 2026: weekly pentosan polysulfate injections for six weeks gave sustained pain-score improvement and increased cartilage volume versus placebo out to 26 weeks in naturally occurring osteoarthritis

Randomized, placebo-controlled trial (publication type: Randomized Controlled Trial, Veterinary; blinding not stated in the record)

Who: Dogs: 20 mixed-breed companion dogs with naturally occurring osteoarthritis, randomised to subcutaneous pentosan polysulfate sodium 3 mg/kg injections (n = 14) or placebo (n = 6) once weekly for six weeks, in a companion-animal clinical research setting. Dogs underwent assessments for pain (Helsinki Chronic Pain Index), functional gait analysis, MRI and biomarker analysis at baseline and selected timepoints out to 26 weeks.

Result: Pentosan polysulfate treatment was well tolerated. At baseline the treated group had higher pain (Helsinki Chronic Pain Index 15.14 vs 8.83 in placebo). Treated dogs experienced sustained Helsinki Chronic Pain Index reductions compared to placebo at 26 weeks after adjusting for differences in baseline pain; gait symmetry normalised up to week 26; total cartilage volume increased at weeks 8 and 26 from baseline compared with placebo; and biomarker changes (CTX-I, HA, TIMP-1) were consistent with slowed cartilage degradation at weeks 8 and 26. The record gives no P values or end-of-study pain scores, so effect sizes cannot be stated from this record.

Watch out: Very small and unbalanced: 14 treated versus only 6 placebo dogs, and the treated group started with substantially worse pain (Helsinki Chronic Pain Index 15.14 vs 8.83), so the headline comparison rests on baseline-adjusted analysis of a tiny sample, with regression to the mean a live alternative explanation. Blinding is not stated in this record and none is claimed for it. Cartilage volume and biomarkers are surrogate, structure-side outcomes.

Stapledon CJM, Krishnan R, Peat RA, Reiter C, Milne ME, Ryan SD, Bauquier SH, Beths T. Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. PLoS One. 2026;21(2):e0342409. PMID: 41666203. Registry ID: none in the record. MeSH: Animals · Dogs · Female · Male · Biomarkers/metabolism · Dog Diseases*/drug therapy · Gait/drug effects · Joints*/drug effects, physiopathology, pathology · Magnetic Resonance Imaging · Osteoarthritis*/drug therapy, veterinary, physiopathology, pathology · Pentosan Sulfuric Polyester*/therapeutic use, pharmacology, administration & dosage · Treatment Outcome

Synthesis: pentosan polysulfate injections probably help some osteoarthritic dogs' clinical scores — POSSIBLE; the oral form showed no clinical benefit

Synthesis

Who: Synthesis of the cards above: Read 1996 (double-blind dose-response study, 40 dogs with chronic osteoarthritis, subcutaneous pentosan polysulphate 0/1/3/5 mg/kg weekly × 4), Innes 2000 (double-blind placebo-controlled trial, oral calcium pentosan polysulphate over one year in post-surgical stifle osteoarthritis) and Stapledon 2026 (randomised placebo-controlled trial, 20 dogs with naturally occurring osteoarthritis, subcutaneous pentosan polysulfate sodium 3 mg/kg weekly × 6, followed to 26 weeks).

Result: (1) Both injection trials favour pentosan polysulfate over placebo on clinical scores: Read on lameness, pain on manipulation and willingness to exercise (best at 3 mg/kg), Stapledon on adjusted chronic-pain scores and gait symmetry sustained to 26 weeks. (2) The one oral trial (Innes) is null on function and radiographic progression over a full year, with only a synovial biomarker difference (P = 0.03). (3) No carded trial reports objective force-plate benefit or a hard clinical endpoint. Two small positive injection trials against one null oral trial support POSSIBLE for injections, scoped away from the oral form.

Watch out: Route and formulation matter on this shelf: the positive evidence is for subcutaneous sodium pentosan polysulfate at 3 mg/kg; the null is for oral calcium pentosan polysulphate after cruciate surgery, and the two should not be merged. A further randomised, blinded, placebo-controlled trial of pentosan polysulfate given after surgical stabilisation of cruciate-deficient stifles (PMID: 17461948) found no differences in lameness score, vertical ground reaction forces or radiographic progression in the main comparison, although, grouped only by initial radiographic score, PPS-treated dogs improved significantly faster in braking ground reaction forces than placebo-treated dogs; it was not carded here because its question is postoperative recovery after cruciate surgery, a different home — it is cross-pointed here as a further caution against reading the injection evidence as strong. This shelf is canine osteoarthritis only; pentosan polysulfate for feline idiopathic cystitis is a separate question (topic #712) and no feline record is carded here.

Synthesis of Read RA et al. PMID: 8683953; Innes JF et al. PMID: 10811265; Stapledon CJM et al. PMID: 41666203. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.